[1] Oldberg A,Franzen A,Heinegard D. Cloning and sequence analysis of rat bone sialoprotein (osteopontin) cDNA reveals an Arg-Gly-Asp cell-binding sequence.Proc Natl Acad Sci USA,1986,83:8819-8823.
[2] Song Z, Chen W, Athavale D, et al. Osteopontin takes center stage in chronic liver disease. Hepatology, 2021,73(4):1594-1608.
[3] Morales-Ibanez O, Dominguez M, Ki SH, et al. Human and experimental evidence supporting a role for osteopontin in alcoholic hepatitis. Hepatology,2013,58:1742-1756.
[4] Nunez-Garcia M, Gomez-Santos B, Buque X, et al. Osteopontin regulates the cross-talk between phosphatidylcholine and cholesterol metabolism in mouse liver. J Lipid Res,2017,58: 1903-1915.
[5] Ge X, Lu Y, Leung TM, et al. Milk osteopontin, a nutritional approach to prevent alcohol-induced liver injury. Am J Physiol Gastrointest Liver Physiol, 2013,304:G929-939.
[6] Ge X, Leung TM, Arriazu E, Lu Y, et al. Osteopontin binding to lipopolysaccharide lowers tumor necrosis factor-alpha and prevents early alcohol-induced liver injury in mice. Hepatology,2014,59:1600-1616.
[7] Ramachandran P, Dobie R, Wilson-Kanamori JR, et al. Resolving the fibrotic niche of human liver cirrhosis at single-cell level. Nature,2019,575:512-518.
[8] Zhang Q, He Y, Luo N, Patel SJ, et al. Landscape and Dynamics of Single Immune Cells in Hepatocellular Carcinoma. Cell,2019,179:829-845 e820.
[9] Sobhy A, Fakhry MM, Azeem HA, et al. Significance of biglycan and osteopontin as non-invasive markers of liver fibrosis in patients with chronic hepatitis B virus and chronic hepatitis C virus. J Investig Med,2019,67:681-685.
[10] Glass O, Henao R, Patel K, et al. Serum Interleukin-8, Osteopontin, and Monocyte Chemoattractant Protein 1 Are Associated With Hepatic Fibrosis in Patients With Nonalcoholic Fatty Liver Disease. Hepatol Commun, 2018,2:1344-1355.
[11] Urtasun R, Lopategi A, George J, et al. Osteopontin, an oxidant stress sensitive cytokine, up-regulates collagen-I via integrin alpha (V) beta (3) engagement and PI3K/pAkt/NFkappaB signaling. Hepatology,2012, 55: 594-608.
[12] Ge X, Arriazu E, Magdaleno F, et al. High Mobility Group Box-1 Drives Fibrosis Progression Signaling via the Receptor for Advanced Glycation End Products in Mice. Hepatology,2018,68: 2380-2404.
[13] Zhu Y, Yang J, Xu D, et al. Disruption of tumour-associated macrophage trafficking by the osteopontin-induced colony-stimulating factor-1 signalling sensitises hepatocellular carcinoma to anti-PD-L1 blockade. Gut,2019,68:1653-1666.
[14] Sun BS, Dong QZ, Ye QH, et al. Lentiviral-mediated miRNA against osteopontin suppresses tumor growth and metastasis of human hepatocellular carcinoma. Hepatology,2008,48: 1834-1842.
[15] Loosen SH, Roderburg C, Kauertz KL, et al. Elevated levels of circulating osteopontin are associated with a poor survival after resection of cholangiocarcinoma. J Hepatol,2017,67: 749-757. |
